DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory Board

DBV Technologies increases expertise in peanut allergy diagnosis and treatment

Paris, France – 19 October 2009 – DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announces the expansion of its Scientific Advisory Board with the appointments of leading paediatric allergy and paediatric food allergy specialists Professor Gideon Lack and Associate Professor Philippe Eigenmann.

In joining DBV Technologies’ Scientific Advisory Board, Professors Lack and Eigenmann provide the Company with access to their expertise in paediatric food allergy diagnosis and treatment. These SAB appointments are of strategic importance to DBV Technologies, as the Company works towards the initiation of its first US Phase I clinical trial for peanut allergy.

Professor Lack is Head of the Children’s Allergy service at Guy’s and St Thomas’ NHS Foundation Trust and a Professor of Paediatric Allergy at King’s College, London, United Kingdom. Professor Lack’s current research is focused on developing novel immunomodulatory treatments for food allergies and new strategies to prevent the development of allergies and asthma in children.

Professor Eigenmann is an Associate Professor at the Department of Infants and Adolescents at the Hospital cantonal Universitaire Geneve (HUG), Geneva, Switzerland, specialising in paediatric allergy diagnosis and treatment. His current research is focused on the pathogenesis of food allergy with regard to sensitization procedures in the bowel, as well as investigating therapeutic food allergy treatment strategies using mouse models.

Commenting on the appointment, DBV Technologies Chairman and CEO Jean François Biry said, “We are delighted to have Professors Lack and Eigenmann’s support behind VIASKIN® and our EPIT peanut allergy desensitization programme. Their outstanding experience in food allergy will help DBV to accelerate our clinical development and significantly increase our scientific capabilities”. 